Sartorius AG

euro adhoc: Sartorius AG
quarterly or semiannual financial statement
Figures for the First Quarter of 2008 Sales revenue rose 3.8% (currency-adjusted: up 7.7%) | Currency-adjusted order intake up 3.4% | EBITA at EUR12.2 million up from the ...

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 22.04.2008 To ensure the best possible comparability, the first-quarter figures of 2007 are shown on a pro forma basis and adjusted for extraordinary expenses. Within the first three months of 2008, the Sartorius Group increased sales revenue by 3.8% to EUR149.2 million (Q1 2007: EUR143.6 mn). Currency-adjusted consolidated sales revenue climbed 7.7%. The Biotechnology Division's sales revenue rose 5.4% (currency-adjusted: +9.5%) to EUR90.6 (Q1 2007: EUR85.9 mn). Sales revenue for the Mechatronics Division grew 1.5% (currency-adjusted: +5.1%) to EUR58.6 million (Q1 2007: EUR57.7 mn). At EUR162.5 million, order intake was higher than sales revenue and thus at the high level of the year-earlier quarter (EUR162.9 mn). On the basis of constant currencies, order intake rose 3.4%. The difference between sales revenue and order intake essentially resulted from the fluctuations in the equipment business of the Biotechnology Division. The Division's order intake was EUR97.6 million (Q1 2007: EUR99.1 million), which corresponds to a decline of 1.5% or a currency-adjusted increase of 2.2%. The value of orders for the Mechatronics Division rose 1.8% or by a currency-adjusted rate of 5.3%. First-quarter operating earnings (earnings before interest, taxes and amortization = EBITA) increased from EUR11.8 million to EUR12.2 million. At 8.2%, the EBITA margin remained unchanged compared to the year-earlier figure. If the EBITA margin had been calculated based on the previous year's exchange rates, it would have increased to more than 9%. EBITA for the Biotechnology Division rose from EUR8.4 million to EUR9.1; for the Mechatronics Division, EBITA at EUR3.1 million was below the year-earlier figure of EUR3.4 million. Net profit after minority interest was EUR3.2 million (Q1 2007: EUR3.5 million); earnings per share (excluding the two non-cash items of amortization and interest on share price warrants granted) were EUR0.25 (Q1 2007: EUR0.26). For the full fiscal year of 2008, the Sartorius Group is continuing to aim at achieving sales revenue growth of more than 9% in constant currencies. Based on this anticipated sales revenue and on an average exchange rate of 1.40 USD/EUR, the Group is planning to increase the EBITA margin to approx. 12%. |EUR in millions |Q1 2008 |Q1 2007 |Change | |(unless otherwise specified) | |pro forma |in % | | | | | | |Sartorius Group | | | | |Sales revenue |149.2 |143.6 |+3.8 (+7.7)| |Order intake |162.5 |162.9 |-0.2 (+3.4)| |EBITA 1) |12.2 |11.8 |+3.7 | |Net profit for the period 1)2) |4.2 |4.4 |-2.9 | |Earnings per share 1)2) in EUR |0.25 |0.26 |-2.9 | | | | | | |Biotechnology Division | | | | |Sales revenue |90.6 |85.9 |+5.4 (+9.5)| |Order intake |97.6 |99.1 |-1.5 (+2.2)| |EBITA 1) |9.1 |8.4 |+8.5 | | | | | | |Mechatronics Division | | | | |Sales revenue |58.6 |57.7 |+1.5 (+5.1)| |Order intake |64.9 |63.8 |+1.8 (+5.3)| |EBITA 1) |3.1 |3.4 |-7.9 | in parentheses: currency-adjusted 1) for 2007 underlying 2) excluding non-cash amortization and, for 2008, additionally excluding non-cash interest expenses for share price warrants Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the quarterly results for Sartorius with analysts and investors in a teleconference at 4:30 p.m. CET following today's Annual Shareholder Meeting. You may dial into this teleconference starting at 4:15 p.m. CET at the following numbers: Germany: +49 (0)69 5007 1316; France: +33 (0)1 70 99 42 99; UK: +44 (0)20 7806 1968; USA: +1 718 354 1387. The dial-in code is 3601455; to view the webcast, log onto www.livemeeting.com/cc/premconfeurope/j oin?id=3601455&role=attend&pw=pw7076 ----------------------- end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Sartorius AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Andreas Wiederhold Treasury & Investor Relations Telefon: +49 (0)551 308-1668 E-Mail: andreas.wiederhold@sartorius.com Branche: Biotechnology ISIN: DE0007165607 WKN: 716560 Index: CDAX, Prime All Share, Technologie All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Hamburg / free trade Börse Stuttgart / free trade Börse Düsseldorf / free trade Börse Hannover / free trade Börse München / free trade

Das könnte Sie auch interessieren: